Design, Synthesis, and Characterization of Fatty Acid Derivatives of a Dimeric Peptide-Based Postsynaptic Density-95 (PSD-95) Inhibitor

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Design, Synthesis, and Characterization of Fatty Acid Derivatives of a Dimeric Peptide-Based Postsynaptic Density-95 (PSD-95) Inhibitor. / Nissen, Klaus B; Andersen, Julie J; Haugaard-Kedström, Linda Maria; Bach, Anders; Strømgaard, Kristian.

In: Journal of Medicinal Chemistry, Vol. 58, 2015, p. 1575-1580.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Nissen, KB, Andersen, JJ, Haugaard-Kedström, LM, Bach, A & Strømgaard, K 2015, 'Design, Synthesis, and Characterization of Fatty Acid Derivatives of a Dimeric Peptide-Based Postsynaptic Density-95 (PSD-95) Inhibitor', Journal of Medicinal Chemistry, vol. 58, pp. 1575-1580. https://doi.org/10.1021/jm501755d

APA

Nissen, K. B., Andersen, J. J., Haugaard-Kedström, L. M., Bach, A., & Strømgaard, K. (2015). Design, Synthesis, and Characterization of Fatty Acid Derivatives of a Dimeric Peptide-Based Postsynaptic Density-95 (PSD-95) Inhibitor. Journal of Medicinal Chemistry, 58, 1575-1580. https://doi.org/10.1021/jm501755d

Vancouver

Nissen KB, Andersen JJ, Haugaard-Kedström LM, Bach A, Strømgaard K. Design, Synthesis, and Characterization of Fatty Acid Derivatives of a Dimeric Peptide-Based Postsynaptic Density-95 (PSD-95) Inhibitor. Journal of Medicinal Chemistry. 2015;58:1575-1580. https://doi.org/10.1021/jm501755d

Author

Nissen, Klaus B ; Andersen, Julie J ; Haugaard-Kedström, Linda Maria ; Bach, Anders ; Strømgaard, Kristian. / Design, Synthesis, and Characterization of Fatty Acid Derivatives of a Dimeric Peptide-Based Postsynaptic Density-95 (PSD-95) Inhibitor. In: Journal of Medicinal Chemistry. 2015 ; Vol. 58. pp. 1575-1580.

Bibtex

@article{de8a778f831b48bab74f2aa43360f32e,
title = "Design, Synthesis, and Characterization of Fatty Acid Derivatives of a Dimeric Peptide-Based Postsynaptic Density-95 (PSD-95) Inhibitor",
abstract = "Dimeric peptide-based inhibitors of postsynaptic density-95 (PSD-95) can reduce ischemic brain damage and inflammatory pain in rodents. To modify the pharmacokinetic profile we designed a series of fatty acid linked dimeric ligands, which potently inhibits PSD-95 and shows improved in vitro blood plasma stability. Subcutaneous administration in rats showed extended stability and sustained release of these ligands. This can facilitate new pharmacological uses of PSD-95 inhibitors and further exploration of PSD-95 as a drug target.",
author = "Nissen, {Klaus B} and Andersen, {Julie J} and Haugaard-Kedstr{\"o}m, {Linda Maria} and Anders Bach and Kristian Str{\o}mgaard",
year = "2015",
doi = "10.1021/jm501755d",
language = "English",
volume = "58",
pages = "1575--1580",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",

}

RIS

TY - JOUR

T1 - Design, Synthesis, and Characterization of Fatty Acid Derivatives of a Dimeric Peptide-Based Postsynaptic Density-95 (PSD-95) Inhibitor

AU - Nissen, Klaus B

AU - Andersen, Julie J

AU - Haugaard-Kedström, Linda Maria

AU - Bach, Anders

AU - Strømgaard, Kristian

PY - 2015

Y1 - 2015

N2 - Dimeric peptide-based inhibitors of postsynaptic density-95 (PSD-95) can reduce ischemic brain damage and inflammatory pain in rodents. To modify the pharmacokinetic profile we designed a series of fatty acid linked dimeric ligands, which potently inhibits PSD-95 and shows improved in vitro blood plasma stability. Subcutaneous administration in rats showed extended stability and sustained release of these ligands. This can facilitate new pharmacological uses of PSD-95 inhibitors and further exploration of PSD-95 as a drug target.

AB - Dimeric peptide-based inhibitors of postsynaptic density-95 (PSD-95) can reduce ischemic brain damage and inflammatory pain in rodents. To modify the pharmacokinetic profile we designed a series of fatty acid linked dimeric ligands, which potently inhibits PSD-95 and shows improved in vitro blood plasma stability. Subcutaneous administration in rats showed extended stability and sustained release of these ligands. This can facilitate new pharmacological uses of PSD-95 inhibitors and further exploration of PSD-95 as a drug target.

U2 - 10.1021/jm501755d

DO - 10.1021/jm501755d

M3 - Journal article

C2 - 25590984

VL - 58

SP - 1575

EP - 1580

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

ER -

ID: 130178670